Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for BridgeBio Pharma (BBIO) over the last 7 years, with Q2 2025 value amounting to $1.9 million.

  • BridgeBio Pharma's Gains from Sales and Divestitures fell 87.79% to $1.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.9 million, marking a year-over-year decrease of 87.79%. This contributed to the annual value of $3.8 million for FY2024, which is 558.06% up from last year.
  • As of Q2 2025, BridgeBio Pharma's Gains from Sales and Divestitures stood at $1.9 million, which was down 87.79% from $879051.0 recorded in Q1 2025.
  • BridgeBio Pharma's Gains from Sales and Divestitures' 5-year high stood at $3.8 million during Q4 2024, with a 5-year trough of $336790.0 in Q1 2022.
  • Its 5-year average for Gains from Sales and Divestitures is $1.6 million, with a median of $1.4 million in 2021.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 4759.26% in 2022, then skyrocketed by 11714.36% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Gains from Sales and Divestitures (Quarter) stood at $1.6 million in 2021, then increased by 24.52% to $2.0 million in 2022, then skyrocketed by 84.67% to $3.6 million in 2023, then grew by 5.58% to $3.8 million in 2024, then plummeted by 49.06% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q2 2025, $879051.0 for Q1 2025, and $3.8 million during Q4 2024.